Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
暂无分享，去创建一个
D. Berry | C. Perou | E. Winer | K. Hoadley | C. Hudis | M. Cheang | B. Pitcher | Baljit Singh | L. Carey | W. Barry | L. Harris | M. Iglesia | C. Anders | C. Cirrincione | D. Ollila | I. Krop | D. Weckstein | N. L. Henry